Actively Recruiting
A Study to Assess the Safety of ARGX-124 in Healthy Volunteers
Led by argenx · Updated on 2026-03-06
104
Participants Needed
1
Research Sites
48 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to assess the safety of ARGX-124 in healthy adults. Another aim is to measure the amount of ARGX-124 in the blood over time to learn how it acts and moves in the body and how the immune system responds to it. Participants will remain in the study for up to approximately 23 weeks.
CONDITIONS
Official Title
A Study to Assess the Safety of ARGX-124 in Healthy Volunteers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Is aged 18 to 65 years and meets the local legal age of consent when signing the consent form
- Is male or a female who is postmenopausal or surgically sterilized (nonchildbearing potential)
- Has a body weight between 50 and 120 kg
- Has a body mass index (BMI) between 18 and 30.5 kg/m2
You will not qualify if you...
- Has any current or past medical or psychiatric condition that could affect study results or increase risk
- Has IgG levels less than 6.0 g/L at screening
- Has a history or current condition causing immunosuppression
- Previously participated in a clinical study involving ARGX-124, ARGX-213, or efgartigimod and received the study drug
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Altasciences
Montreal, Canada, H3P 3P1
Actively Recruiting
Research Team
S
Sabine Coppieters, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here